

Patient Card

Safety Information about Venclyxto[®] (venetoclax) for Patients with Chronic Lymphocytic Leukemia (CLL)

Venclyxto[®] is used to treat patients with CLL. This card contains information you need to know about Tumour Lysis Syndrome and Venclyxto[®].



- **Keep this patient card with you all the time.**
- **Show it to any doctor involved in your medical care or if you go to the emergency department.**
- **Always take Venclyxto[®] exactly as your doctor has told you to.**

What should I know about TLS?

During your treatment, you may develop high levels of certain body salts (such as potassium and uric acid) in the blood. This can lead to a condition called **Tumour Lysis Syndrome** (TLS) within the first 5 weeks of treatment.

TLS symptoms:

- fever or chills
- nausea or vomiting
- feeling confused
- feeling short of breath
- irregular heart beat
- dark or cloudy urine
- feeling unusually tired
- muscle pain or joint pain
- fits or seizures
- abdominal pain and bloating

What should I do if I get TLS symptoms?

If you experience any TLS symptoms during your treatment, you should:



Call your doctor or seek medical attention immediately, and



Stop taking Venclyxto®

Read the Package Leaflet (PL) for more information.

Reporting of side effects: You can report side effects to Fimea or to the local representative of the marketing authorisation holder (AbbVie Oy)

AbbVie Oy
Tel. 010 2411 200
www.abbvie.fi

Finnish Medicines Agency Fimea
Register for adverse drug reactions
P.O. Box 55, FI-00034 FIMEA | www.fimea.fi

How can I reduce my risk of getting TLS?



Drink at least **1.5 to 2 liters of water daily**:

- ✓ starting from 2 days before your first dose, and
- ✓ on the day of your first dose, and
- ✓ every day during first 5 weeks of treatment. Drinking plenty of water will help to remove high levels of blood salts through your urine.



Attend your scheduled **blood test appointments**, as they will help your doctor identify TLS.



Before your treatment with Venclyxto®, start another medicine that helps prevent the build-up of the blood salt (uric acid) in your body, as instructed by your doctor.



Important Safety Information for Healthcare Professionals about Venclyxto® and TLS

This patient is taking Venclyxto® for CLL which may cause Tumour Lysis Syndrome (TLS) in the first 5 weeks of treatment.

- ✓ Evaluate blood chemistries: potassium, uric acid, phosphorus, calcium and creatinine.
- ✓ Urgently correct blood chemistry abnormalities. **This can be fatal, if left untreated.**
- ✓ If you suspect TLS, contact prescribing doctor listed on this card immediately.

Please consult the Summary of Product Characteristics (SmPC) or contact AbbVie at 010 2411 200 for more information and if you need additional copies of the patient card.

Important Contact Details

My name:

My emergency contact (name and phone number):

Doctor's name – who prescribed Venclyxto[®]:

Doctor's contact phone number:

Version 1.0. April 7, 2021.

FI-VNCCLL-240002/RMP/13.03.2024

abbvie